Top

International Journal of Clinical Oncology

Published in:

01-02-2013 | Original Article

Immunohistochemical location of the p75 neurotrophin receptor (p75NTR) in oral leukoplakia and oral squamous cell carcinoma

Authors: Takahiro Kiyosue, Shintaro Kawano, Ryota Matsubara, Yuichi Goto, Mitsuhiro Hirano, Teppei Jinno, Takeshi Toyoshima, Ryoji Kitamura, Kazunari Oobu, Seiji Nakamura

Published in: International Journal of Clinical Oncology | Issue 1/2013

Abstract

Background

Recent studies have demonstrated that the p75 neurotrophin receptor (p75NTR) is a useful marker of keratinocyte stem cells. Although the stem cell markers of original normal tissue have been used to identify cancer stem cells in a variety of cancers, the expression and function of p75NTR have been poorly understood in oral squamous cell carcinoma (OSCC). The objective of this study is, thus, to examine p75NTR expression immunohistochemically in oral leukoplakia (OL), the most frequent precancerous lesion, and OSCC, and to reveal the usefulness of p75NTR as a marker for undifferentiated cancer cells and a novel prognostic factor for OSCC patients.

Methods

In this study immunohistochemical expression of p75NTR, Ki-67, cytokeratin (CK) 5, and CK14 was examined in 112 cases of OL and 81 of OSCC. The labeling indices (LIs) of p75NTR and Ki-67 were calculated, and the association of these LIs with histopathologic characteristics was then evaluated.

Results

In the normal oral epithelium and OL, p75NTR was expressed only in the basal layer, and its LI was invariant, irrespective of the extent of epithelial dysplasia. In OSCC, however, p75NTR-LI was significantly increased in association with upgrading of histologic grade and mode of tumor invasion. Furthermore, the prognosis of the high p75NTR-LI group (LI ≥ 53.1%) was poorer than that of the low p75NTR-LI group (LI < 53.1%).

Conclusions

These results suggest that p75NTR is expressed in undifferentiated cell populations in OL and OSCC. Furthermore, p75NTR is possibly involved in invasion and poor prognosis in OSCC.

Parkin DM, Bray F, Ferlay J et al (2001) Estimating the world cancer burden: Globocan 2000. Int J Cancer 94:153–156PubMedCrossRef

Parkin DM, Bray F, Ferlay J et al (2005) Global cancer statistics, 2002. CA Cancer J Clin 55:74–108PubMedCrossRef

Breakhuis BJM, Brakenhoff RH, Leemans CR (2005) Second field tumors: a new opportunity for cancer prevention? Oncologist 10:493–500CrossRef

Bonnet D, Dick JE (1997) Human acute myeloid leukemia is organized as a hierarchy that originates from a primitive hematopoietic cell. Nat Med 3:730–737PubMedCrossRef

Al-Haji M, Wicha MS, Benito-Herandez A et al (2003) Prospective identification of tumorigenic breast cancer cells. Proc Natl Acad Sci USA 100:3983–3988CrossRef

Singh SK, Hawkins C, Clarke ID et al (2004) Identification of human brain tumour initiating cells. Nature 432:396–401PubMedCrossRef

Hemmati HD, Nakano I, Lazareff JA et al (2003) Cancerous stem cells can arise from pediatric brain tumors. Proc Natl Acad Sci USA 100:15178–15183PubMedCrossRef

Ma S, Chan KW, Hu L et al (2007) Identification and characterization of tumorigenic liver cancer stem/progenitor cells. Gastroenterology 132:2542–2556PubMedCrossRef

Zen Y, Fujii T, Yoshikawa S et al (2007) Histological and culture studies with respect to ABCG2 expression support the existence of a cancer cell hierarchy in human hepatocellular carcinoma. Am J Pathol 170:1750–1762PubMedCrossRef

10.

Singh SK, Clarke ID, Tearasaki M et al (2003) Identification of a cancer stem cell in human brain tumors. Cancer Res 63:5821–5828PubMed

11.

Liu S, Dontsu G, Mantle ID et al (2006) Hedgehog signaling and Bmi-1 regulate self-renewal of normal and malignant human mammary stem cells. Cancer Res 66:6063–6071PubMedCrossRef

12.

Seo DC, Sung JM, Cho HJ et al (2007) Gene expression profiling of cancer stem cell in human lung adenocarcinoma A549 cells. Mol Cancer 6:75PubMedCrossRef

13.

Ricci-Vitiani L, Lombardi DG, Pilozzi E et al (2007) Identification and expansion of human colon-cancer-initiating cells. Nature 445:111–115PubMedCrossRef

14.

Li C, Heidt DG, Dalerba P et al (2007) Identification of pancreatic cancer stem cells. Cancer Res 67:1030–1037PubMedCrossRef

15.

Mitsutake N, Iwao A, Nagai K et al (2007) Characterization of side population in thyroid cancer cell lines: cancer stem-like cells are enriched partly but not exclusively. Endocrinology 148:1797–1803PubMedCrossRef

16.

Bao S, Wu Q, McLendon RE et al (2006) Glioma stem cells promote radioresistence by preferential activation of the DNA damage response. Nature 444:756–760PubMedCrossRef

17.

Liu G, Yuan X, Zeng Z et al (2006) Analysis of gene expression and chemoresistance of CD133⁺ cancer stem cells in glioblastoma. Mol Cancer 5:67PubMedCrossRef

18.

Prince ME, Sivanandan R, Kaczorowski A et al (2007) Identification of a subpopulation of cells with cancer stem cell properties in head and neck squamous cell carcinoma. Proc Natl Acad Sci USA 104:973–978PubMedCrossRef

19.

Chikamatsu K, Takahashi G, Sakakura K et al (2010) Immunoregulatory properties of CD44⁺ cancer stem-like cells in squamous cell carcinoma of the head and neck. Head Neck (in press)

20.

Zhang P, Zhang Y, Mao L et al (2009) Side population in oral squamous cell carcinoma possesses tumor stem cell phenotypes. Cancer lett 277:227–234PubMedCrossRef

21.

Harper LJ, Piper K, Common J et al (2007) Stem cell patterns in cell lines derived from head and neck squamous cell carcinoma. J Oral Pathol Med 36:594–603PubMedCrossRef

22.

Dean M, Fojo T, Bates S (2005) Tumor stem cells and drug resistance. Nat Rev Cancer 5:275–284PubMedCrossRef

23.

Okumura T, Shimada Y, Imamura M et al (2003) Neurotrophin receptor p75^NTR characterizes human esophageal keratinocyte stem cells in vitro. Oncogene 22:4017–4026PubMedCrossRef

24.

Nakamura T, Endo K, Kinoshita S (2007) Identification of human oral keratinocyte stem/progenitor cells by neurotrophin receptor p75 and the role of neurotrophin/p75 signaling. Stem cells 25:628–638PubMedCrossRef

25.

Rodriguez-Tebar A, Dechant G, Gotz R et al (1992) Binding of neurotrophin-3 to its neuronal receptors and interactions with nerve growth factor and brain-derived neurotrophic factor. EMBO J 11:917–922PubMed

26.

Wang X, Bauer JH, Li Y et al (2001) Characterization of a p75(NTR) apoptotic signaling pathway using a novel cellular model. J Biol Chem 276:33812–33820PubMedCrossRef

27.

Krygier S, Djakiew D (2002) p75 suppresses growth and NGF mediated metastasis of human prostate cancer cells. Int J Cancer 98:1–7PubMedCrossRef

28.

Khwaja F, Djakiew D (2003) Inhibition of cell-cycle effectors of proliferation in bladder tumor epithelial cells by the p75NTR tumor suppressor. Mol Carcinog 36:153–160PubMedCrossRef

29.

Pflug BR, Onoda M, Lynch JH et al (1992) Reduced expression of the low affinity nerve growth factor receptor in benign and malignant human prostate tissue and loss of expression in four human metastatic prostate tumor cell lines. Cancer Res 52:5403–5406PubMed

30.

Gale N, Pilch BZ, Sindramsky D et al (2005) World Health Organization classification of tumors. Pathology and genetics of head and neck tumors. Iarc Press, Lyon, pp 177–179

31.

Sobin LH, Witte Sobin LH, Wittekind Ch (eds) (2002) TNM classification of malignant tumors. Wiley-Liss, Inc., New York

32.

Yamamoto E, Miyakawa A, Kohama G et al (1984) Mode of invasion and lymph node metastasis in squamous cell carcinoma of the oral cavity. Head Neck Surg 6:938–947PubMedCrossRef

33.

Lehrer MS, Sun TT, Lavker RM (1998) Strategies of epithelial repair: modulation of stem cell and transit amplifying cell proliferation. J Cell Sci 111:2867–2875PubMed

34.

Morris RJ, Potten CS (1994) Slowly cycling (label-retaining) epidermal cells behave like clonogenic stem cells in vitro. Cell Prolif 27:279–289PubMedCrossRef

35.

Takeda T, Sugihara K, Hirayama Y et al (2006) Immunohistological evaluation of Ki-67, p63, CK19 and p53 expression in oral epithelial dysplasias. J Oral Pathol Med 35:369–375PubMedCrossRef

36.

Okumura T, Tsunoda S, Mori Y et al (2006) The biological role of the low-affinity p75 neurotrophin receptor in esophageal squamous cell carcinoma. Clin Cancer Res 12:5096–5103PubMedCrossRef

37.

Søland TM, Brusevold IJ, Koppang HS et al (2008) Nerve growth factor receptor (p75^NTR) and pattern of invasion predict poor prognosis in oral squamous cell carcinoma. Histopahology 53:62–67CrossRef

38.

Tsunoda S, Okumura T, Ito T et al (2006) Significance of nerve growth factor overexpression and its autocrine loop in oesophageal squamous cell carcinoma. Br J cancer 95:322–330PubMedCrossRef

39.

Dang C, Zhang Y, Ma Q et al (2006) Expression of nerve growth factor receptors is correlated with progression and prognosis of human pancreatic cancer. J Gastroenterol Hepatol 21:850–858PubMedCrossRef

40.

Roux PP, Barker PA (2002) Neurotrophin signaling through the p75 neurotrophin receptor. Prog Neurobiol 67:203–233PubMedCrossRef

41.

Barker P, Shooter E (1994) Disruption of NGF binding to the low affinity neurotrophin receptor p75NTR reduces NGF binding to TrkA on PC12 cells. Neuron 13:203–215PubMedCrossRef

42.

Lee KF, Bachman K, Landis S et al (1994) Dependence on p75 for innervation of some sympathetic targets. Science 263:1447–1449PubMedCrossRef

43.

Van der Zee CE, Ross GM, Riopelle RJ et al (1996) Survival of cholinergic forebrain neurons in the developing p75 (NGFR) deficient mice. Science 274:1729–1732PubMedCrossRef

44.

Dolle L, Adriaenssens E, EI-Yazidi-Belkoura I et al (2004) Nerve growth factor receptors and signaling in breast cancer. Curr Cancer Drug Targets 4:463–470PubMedCrossRef

45.

Descamps S, Toillon RA, Adriaenssens E et al (2001) Nerve growth factor stimulates proliferation and survival of human breast cancer cells through two distinct signaling pathways. J Biol Chem 276:17864–17870PubMedCrossRef

Title: Immunohistochemical location of the p75 neurotrophin receptor (p75NTR) in oral leukoplakia and oral squamous cell carcinoma
Authors: Takahiro Kiyosue
Shintaro Kawano
Ryota Matsubara
Yuichi Goto
Mitsuhiro Hirano
Teppei Jinno
Takeshi Toyoshima
Ryoji Kitamura
Kazunari Oobu
Seiji Nakamura
Publication date: 01-02-2013
Publisher: Springer Japan
Published in: International Journal of Clinical Oncology / Issue 1/2013
Print ISSN: 1341-9625
Electronic ISSN: 1437-7772
DOI: https://doi.org/10.1007/s10147-011-0358-4

Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras

Prof. Fabrice Barlesi

Developed by: Springer Medicine

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Background

Methods

Results

Conclusions

Please log in to get access to this content

Other articles of this Issue 1/2013

Comparison of safety and efficacy of S-1 monotherapy and S-1 plus cisplatin therapy in elderly patients with advanced gastric cancer

Carboplatin–gemcitabine combination chemotherapy upregulates AKR1B10 expression in bladder cancer

Third-line sunitinib following sequential use of cytokine therapy and sorafenib in Japanese patients with metastatic renal cell carcinoma

Neoadjuvant and adjuvant chemotherapy with modified mesna, adriamycin, ifosfamide, and dacarbazine (MAID) regimen for adult high-grade non-small round cell soft tissue sarcomas

Can docetaxel therapy improve overall survival from primary therapy compared with androgen-deprivation therapy alone in Japanese patients with castration-resistant prostate cancer? A multi-institutional cooperative study

Difference in survival and prognostic factors between smokers and never-smokers with advanced non-small-cell lung cancer

Keynote webinar | Spotlight on antibody–drug conjugates in cancer